Table 2 Association between baseline EV miRNA expression and mCRC patient characteristics. Mann-Whitney U and Kruskal-Wallis tests were used. Abbreviations: CTCs: Circulating tumour cells; miR: miRNA; B: Baseline; 12w: 12 weeks; 24w: 24weeks; *p < 0.05.

From: Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients

		n	miR-19b		miR-21		miR-222		miR-92a
		n	median	p	median	p	median	p	median	p
Gender	Male	30	3.756	0.364	7.191	0.529	2.848	0.087	3.696	0.940
Gender	Female	14	3.146	0.364	8.588	0.529	4.437	0.087	3.079	0.940
Age (years)	<55	13	3.546	0.495	5.759	0.463	1.748	0.017*	2.886	0.389
Age (years)	>55	31	4.455	0.495	7.831	0.463	4.762	0.017*	3.616	0.389
Primary tumour location	Colon	23	3.569	0.916	3.329	0.647	3.226	0.245	5.518	0.169
Primary tumour location	Rectum	21	3.546	0.916	7.809	0.647	3.106	0.245	3.203	0.169
Metastasis location	Liver	23	3.020	0.087	9.561	0.687	4.155	0.519	3.571	0.280
	Lung	13	4.986	0.087	7.155	0.687	2.661	0.519	2.439	0.280
	Other	6	0.343		7.422		2.709		5.748
Metachronous metastasis	No	39	3.820	0.386	7.809	0.216	3.478	0.802	3.571	0.858
Metachronous metastasis	Yes	5	2.800	0.386	5.080	0.216	3.106	0.802	3.203	0.858
Metastasis surgery	No	29	3.546	0.811	7.831	0.591	3.019	0.185	3.342	0.835
Metastasis surgery	Yes	11	3.569	0.811	5.759	0.591	5.101	0.185	3.185	0.835
K-RAS status	Wild-type	22	2.789	0.053	7.724	0.347	4.768	0.143	3.696	0.010*
K-RAS status	Mutated	19	5.061	0.053	5.462	0.347	3.035	0.143	2.340	0.010*
CEA (B)	Standard	10	2.319	0.534	7.025	0.128	2.588	0.534	2.560	0.312
CEA (B)	High	34	3.882	0.534	13.151	0.128	3.352	0.534	3.696	0.312
CA 19.9 (B)	Standard	19	3.271	0.855	7.227	0.448	3.117	0.734	2.681	0.182
CA 19.9 (B)	High	22	4.138	0.855	11.242	0.448	3.123	0.734	3.696	0.182
CEA (12w)	Standard	15	3.943	0.699	6.822	0.376	4.155	0.192	2.681	0.720
CEA (12w)	High	25	3.546	0.699	13.378	0.376	3.019	0.192	3.571	0.720
CA 19.9 (12w)	Standard	22	3.420	0.527	7.242	0.840	3.817	0.240	3.194	0.840
CA 19.9 (12w)	High	18	3.6883	0.527	10.377	0.840	2.481	0.240	3.524	0.840
CEA (24w)	Standard	15	3.943	0.539	7.329	0.658	4.155	0.270	2.681	0.539
CEA (24w)	High	24	3.557	0.539	13.151	0.658	3.027	0.270	3.673	0.539
CA 19.9 (24w)	Standard	22	3.695	0.455	7.473	0.737	4.346	0.042*	3.035	0.781
CA 19.9 (24w)	High	16	4.001	0.455	6.114	0.737	2.185	0.042*	3.673	0.781
Response (12w)	Non-favourable	17	3.569	0.747	7.227	0.547	3.035	0.510	3.775	0.362
Response (12w)	Favourable	22	3.146	0.747	7.219	0.547	3.817	0.510	2.667	0.362
Response (24w)	Non-favourable	24	3.408	0.318	8.696	0.420	3.076	0.672	4.052	0.795
Response (24w)	Favourable	16	4.428	0.318	6.142	0.420	3.631	0.672	3.194	0.795
Progression	No	9	4.455	0.353	6.822	0.268	5.681	0.471	2.681	0.736
Progression	Yes	34	3.420	0.353	7.820	0.268	3.112	0.471	3.594	0.736
Death	No	6	3.728	0.934	5.115	0.193	2.822	0.677	3.983	0.652
Death	Yes	38	3.557	0.934	7.713	0.193	3.171	0.677	3.524	0.652
CTC (B)	Negative	27	3.943	0.392	12.923	0.477	4.155	0.604	3.616	0.539
CTC (B)	Positive	17	3.020	0.392	7.227	0.477	3.106	0.604	2.681	0.539
CTC (12w)	Negative	24	3.557	0.943	7.473	0.875	4.246	0.146	2.9333	0.383
CTC (12w)	Positive	15	4.455	0.943	6.822	0.875	2.301	0.146	3.571	0.383
CTC (24w)	Negative	27	3.569	0.505	5.462	0.023*	3.019	0.251	2.439	0.308
CTC (24w)	Positive	11	6.855	0.505	17.722	0.023*	5.101	0.251	3.342	0.308

Back to article page

Table 2 Association between baseline EV miRNA expression and mCRC patient characteristics. Mann-Whitney U and Kruskal-Wallis tests were used. Abbreviations: CTCs: Circulating tumour cells; miR: miRNA; B: Baseline; 12w: 12 weeks; 24w: 24weeks; *p < 0.05.

Search

Quick links